Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Joanna Horobin"'
Autor:
Julie A. Brevard, Olga Polyanskaya, Victoria P. Werth, David Fiorentino, Mark Hurtt, James Baker, Joanna Horobin
Publikováno v:
Journal of Clinical & Experimental Dermatology Research.
Objective: Skin inflammation is a universal characteristic of the multisystem inflammatory myopathy dermatomyositis (DM). About 35% of DM patients have a polycyclic or chronic disease course, usually due to active skin disease, despite standard of ca
Autor:
Toshio Shimizu, Mahesh Padval, Masayuki Takeda, Tutomu Iwasa, Joanna Horobin, Takeshi Yoshida, Ajit Chavan, Mitchell Keegan, Kazuhiko Nakagawa, Lou Vaickus, Kazuya Fukuoka
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity
Autor:
Joanna Horobin, Lee M. Krug, Richard J. Gralla, Marjorie G. Zauderer, Dean A. Fennell, Mitchell Keegan, Anna K. Nowak, Hedy L. Kindler, Paul Baas
Publikováno v:
Journal of Clinical Oncology. 32:TPS7611-TPS7611
TPS7611 Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor in the pleural lining of the lung usually caused by asbestos exposure. Median OS following frontline chemotherapy wit...
Autor:
Mahesh Padval, Anne Poli, Suzanne F. Jones, Howard A. Burris, Kathleen N. Moore, Mitchell Keegan, Manish R. Patel, Joanna Horobin, Jeffrey R. Infante
Publikováno v:
Journal of Clinical Oncology. 32:5521-5521
5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to reduce tumor growth and metastasis through inhibition of tumor cell surv...
Autor:
Daniel Morgensztern, D. Ross Camidge, Pier Paolo Scaglioni, Rachel Sorensen, Timothy F. Burns, Ariel Lopez-Chavez, Mitchell Keegan, Suresh S. Ramalingam, Ahmad Mouhamad Wehbe, David T. Weaver, David E. Gerber, Joanna Horobin, Ronan J. Kelly, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 32:TPS8126-TPS8126
TPS8126 Background: KRAS mutations have been associated with poor prognosis in NSCLC and resistance to epidermal growth factor (EGFR) tyrosine kinase inhibitors. FAK represents a therapeutic target...
Autor:
Vihren N. Kolev, Mahesh Padval, Mitchell Keegan, Qunli Xu, Christian M. Vidal, Joanna Horobin, Irina M. Shapiro, Daniel Paterson, Jonathan A. Pachter, Quentin G. Wright
Publikováno v:
Journal of Clinical Oncology. 31:e13523-e13523
e13523 Background: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that orchestrates cellular signaling through integrins and growth factor receptors and functions in multiple steps of tumorigenesis. Both VS-6063 and VS-4718 are potent,